Head-to-Head Comparison
DynaMed vs Epocrates: Which Is Better for Physicians?
DynaMed: Evidence-Based Clinical Decision Support by EBSCO Epocrates: Drug Reference, Interaction Checker & Clinical Decision Support
Updated
Direct Answer
Source: Clinical AI Report, 2026
Key takeaways
- DynaMed starts at $399 a year in the US (October 2026); Epocrates is free for drug basics, and Epocrates Plus costs $179.99 a year.
- DynaMed gives explicit levels of evidence for its content, while Epocrates Plus disease content lacks the depth of DynaMed or UpToDate.
- Epocrates offers a fast mobile interaction checker and pill identifier; DynaMedex pairs DynaMed with Micromedex drug information for $599 a year.
- DynaMed offers Dyna AI conversational answers in a $475-a-year plan and offline mobile access, while Epocrates has no natural-language search or AI clinical reasoning.
Feature Comparison
| Feature | DynaMed | Epocrates |
|---|---|---|
| Rating | DynaMed: Fair | Epocrates: Fair |
| Category | DynaMed: Clinical Reference & Decision Support | Epocrates: Drug Reference & Clinical Decision Support |
| Pricing | DynaMed: From $399/year Individual | Epocrates: Free (Basic) / $179.99/year (Plus) |
| Founded | DynaMed: 2004 | Epocrates: 1998 |
| Headquarters | DynaMed: Ipswich, MA | Epocrates: San Mateo, CA |
| Evidence Citations | DynaMed: Yes | Epocrates: No |
| AI Differential Diagnosis | DynaMed: No | Epocrates: No |
| Drug Database | DynaMed: Yes | Epocrates: Yes |
| Drug Interaction Checker | DynaMed: No | Epocrates: Yes |
| Medical Calculators | DynaMed: Yes | Epocrates: Yes |
| Natural Language Search | DynaMed: Yes | Epocrates: No |
| Document & Image Upload | DynaMed: No | Epocrates: No |
| EHR Integration | DynaMed: Yes | Epocrates: No |
| Mobile App | DynaMed: Yes | Epocrates: Yes |
| Built-in Dialer | DynaMed: No | Epocrates: No |
| AI Clinical Scribe | DynaMed: No | Epocrates: No |
| CME Credits | DynaMed: Yes | Epocrates: No |
| Multi-Language | DynaMed: No | Epocrates: No |
Strengths & Limitations
DynaMed
Strengths
- +Best in KLAS for Clinical Decision Support four times (2021, 2022, 2024, 2025)
- +3,400+ clinical topics with daily updates from 500+ journal surveillance
- +Explicit levels of evidence and grades of recommendation for all content
- +DynaMedex bundle integrates Micromedex drug information
- +Lower individual pricing than UpToDate ($399/year vs $579/year)
- +Dyna AI generative assistant grounded in curated evidence (launched 2024)
- +EHR integration via HL7 Infobutton and toolbar links
- +CME/MOC credit tracking built in
Limitations
- –Lower brand recognition than UpToDate among physicians
- –Fewer clinical topics than UpToDate (3,400 vs 12,000+)
- –Dyna AI is an add-on cost ($475/year vs $399/year base)
- –AI features are newer and less mature than dedicated CDS platforms
- –Shared decision-making tools (DynaMed Decisions) require separate licensing
- –No free tier for individual physicians
Epocrates
Strengths
- +Free tier with genuinely useful drug interaction checker and monographs
- +Fast, well-designed mobile app optimized for point-of-care use
- +Over 1 million active healthcare professional users
- +Includes a pill identification tool
- +Affordable Plus tier at $179.99/year compared to competitors
- +Long track record since 1998 with consistent reliability
Limitations
- –No AI-powered differential diagnosis or clinical reasoning
- –Disease content lacks depth compared to UpToDate or DynaMed
- –No natural-language query support or evidence synthesis
- –Limited EHR integration for individual users
- –Plus tier content updates can lag behind newer platforms
Key Statistics
DynaMed
Epocrates
Citable Summaries
DynaMed
DynaMed has an editorial score of 59/100 (3.0/5), calculated from Clinical AI Report's published criteria weights. It ranks #7 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.
Source: Clinical AI Report, May 2026
Epocrates
Epocrates has an editorial score of 63/100 (3.2/5), calculated from Clinical AI Report's published criteria weights. It ranks #6 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.
Source: Clinical AI Report, May 2026
Our Assessment
In our 2026 evaluation, Epocrates (ranked #6, 3.2 stars) outperforms DynaMed (ranked #7, 3 stars) in overall physician satisfaction and editorial scoring. Epocrates is best suited for physicians and residents seeking a fast, reliable, mobile-first drug reference tool with a strong free tier — especially for interaction checks and dosing at the point of care. Meanwhile, DynaMed is a stronger choice for physicians and institutions seeking a KLAS-recognized, evidence-graded clinical reference at a lower price point than UpToDate, with integrated drug information via Micromedex. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.